IPH4102 is a first-in-class anti-KIR3DL2 antibody Phase I is expected to start in 2015 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing...

Data on primary efficacy endpoint Leukemia-Free Survival expected end of 2015 Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in...

This press release may not be distributed directly or indirectly in Canada, Australia or Japan. This press release is not offering material and is for information purposes only. Innate Pharma S.A....

This press release may not be distributed directly or indirectly in Canada, Australia or Japan. This press release is not offering material and is for information purposes only. Innate pharma launches...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces revenue of...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today holds an R&D...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced the...

Approval of issuance of 600,000 shares reserved to Novo Nordisk A/S as contemplated by the agreement on NKG2A checkpoint inhibitor acquisition by Innate Pharma Innate Pharma (Euronext Paris...

Innate Pharma will update investors and analysts on its pipeline and strategy The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data...